(Q34150448)

English

Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

1 reference

based on heuristic

inferred from title

object named as

vaccinia virus

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

10

object named as

Jeffrey Schlom

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

James L. Gulley

1

object named as

James Gulley

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Seth M Steinberg

6

object named as

Seth M Steinberg

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

3

object named as

William Dahut

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

author name string

Alice P Chen

2

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Philip M Arlen

4

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Anne Bastian

5

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Kwong Tsang

7

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Dennis Panicali

8

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Diane Poole

9

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

J Michael Hamilton

11

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

publication date

1 October 2002

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

53

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

109-117

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10130

21 January 2018

In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10130

21 January 2018

Expression of human prostate-specific antigen (PSA) in a mouse tumor cell line reduces tumorigenicity and elicits PSA-specific cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10130

21 January 2018

A recombinant vaccinia virus expressing human prostate‐specific antigen (PSA): Safety and immunogenicity in a non‐human primate

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10130

21 January 2018

The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10130

21 January 2018

Generation of Human Cytotoxic T Cells Specific for Human Carcinoembryonic Antigen Epitopes From Patients Immunized With Recombinant Vaccinia-CEA Vaccine

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10130

21 January 2018

Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10130

21 January 2018

Characterization ofin VivoPrimary and Secondary CD8+T Cell Responses Induced by Recombinant Influenza and Vaccinia Viruses

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10130

21 January 2018

Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10130

21 January 2018

Uses of granulocyte-macrophage colony-stimulating factor in vaccine development

1 reference

https://api.crossref.org/works/10.1002%2FPROS.10130

21 January 2018

Identifiers

10.1002/PROS.10130

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34150448&oldid=2050726334"